International Immunology, Vol. 13, No. 7, 877-885,
July 2001
© 2001 Japanese Society for Immunology
Degeneracy and additional alloreactivity of drug-specific human 
ß+ T cell clones
Correspondence to: W. J. Pichler
It has been well established that T cells can recognize small mol. wt compounds such as drugs. Results from previous studies revealing a high heterogeneity and cross-reactivity of drug-specific T cell clones (TCC) in individual patients prompted us to analyze the degeneracy of drug-reactive TCR in detail. Hence, we analyzed the MHC restriction pattern of a panel of 100 drug-specific TCC isolated from different drug-allergic donors. We found that 28 of the tested clones showed an MHC allele-unrestricted drug recognition. Most of these clones were at the same time highly drug specific, i.e. they could only be stimulated by the original drug and not by any drug derivatives. In contrast, TCC with the ability to interact with different drug derivatives displayed a clearly MHC allele-restricted drug recognition. Therefore, we concluded that the TCR of these clones is mainly interacting with side chains of the appropriate drug molecules and hence able to tolerate alterations in the MHC molecule. Moreover, we tested all clones for additional alloreactivity and found that 27 clones could be stimulated by a self-MHC–peptide–drug complex as well as by a non-self-MHC–peptide complex. This cross-reactivity with allogeneic MHC molecules was substantially higher in drug-specific TCC compared to tetanus toxoid-specific clones from the same donors. This suggests that from the point of view of drug-specific TCR, non-self-MHC–peptide complexes have a higher incidence to mimic the `original' self-MHC–peptide–drug complex and this may occur for TCR recognizing self-MHC–pathogen-derived peptide complexes. Finally, the biological functions of bispecific TCC were not influenced by the nature of the stimulating ligand. Both drug as well as allogeneic stimulation led to similar reaction patterns in the analyzed TCC.
Keywords: allergy, allorecognition, drug, non-peptide antigens, T cells
Transmitting editor: A. McMichael
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. A. Schmid, J. P. H. Depta, M. Luthi, and W. J. Pichler Transfection of Drug-Specific T-Cell Receptors into Hybridoma Cells: Tools to Monitor Drug Interaction with T-Cell Receptors and Evaluate Cross-Reactivity to Related Compounds Mol. Pharmacol., July 1, 2006; 70(1): 356 - 365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Naisbitt, J. Farrell, P. J. Chamberlain, J. E. Hopkins, N. G. Berry, M. Pirmohamed, and B. K. Park Characterization of the T-Cell Response in a Patient with Phenindione Hypersensitivity J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 1058 - 1065. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. J. Pichler Delayed Drug Hypersensitivity Reactions Ann Intern Med, October 21, 2003; 139(8): 683 - 693. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Farrell, D. J. Naisbitt, N. S. Drummond, J. P. H. Depta, F. J. Vilar, M. Pirmohamed, and B. K. Park Characterization of Sulfamethoxazole and Sulfamethoxazole Metabolite-Specific T-Cell Responses in Animals and Humans J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 229 - 237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Naisbitt, M. Britschgi, G. Wong, J. Farrell, J. P. H. Depta, D. W. Chadwick, W. J. Pichler, M. Pirmohamed, and B. K. Park Hypersensitivity Reactions to Carbamazepine: Characterization of the Specificity, Phenotype, and Cytokine Profile of Drug-Specific T Cell Clones Mol. Pharmacol., March 1, 2003; 63(3): 732 - 741. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Hashizume, M. Takigawa, and Y. Tokura Characterization of Drug-Specific T Cells in Phenobarbital- Induced Eruption J. Immunol., May 15, 2002; 168(10): 5359 - 5368. [Abstract] [Full Text] [PDF]
|
|